73 results on '"Ness SA"'
Search Results
2. The immune response to a fungus in pancreatic cancer samples
- Author
-
Brayer, KJ, primary, Hanson, JA, additional, Cingam, S, additional, Martinez, C, additional, Ness, SA, additional, and Rabinowitz, I, additional
- Published
- 2023
- Full Text
- View/download PDF
3. Absolute myocardial blood flow determination using real-time myocardial contrast echocardiography during adenosine stress: comparison with single-photon emission computed tomography.
- Author
-
Abdelmoneim SS, Dhoble A, Bernier M, Moir S, Hagen ME, Ness SA, Abdel-Kader SS, Pellikka PA, and Mulvagh SL
- Abstract
OBJECTIVE: To assess the feasibility and diagnostic accuracy of real-time myocardial contrast echocardiography (MCE)-derived absolute myocardial blood flow for detection of myocardial perfusion abnormalities compared with simultaneous technetium 99 m sestamibi single-photon emission computed tomography (SPECT). DESIGN: Prospective study. SETTING: Tertiary-care medical institution. PATIENTS: 79 patients with known or suspected coronary artery disease. INTERVENTIONS: Simultaneous SPECT and real-time MCE during adenosine stress. MAIN OUTCOME MEASURES: Absolute myocardial blood flow (MBF, ml/min/g), microbubble velocity (beta, min(-1)), and reserve values. Endpoints included sensitivity, specificity, positive likelihood ratio (LR+) or negative likelihood ratio (LR-) and area under the curve (AUC) of the receiver operating characteristic curve. RESULTS: Reserve measurements were feasible in 975 of 1343 segments (73%); of these, 130 segments (13%) were abnormal by SPECT. MCE perfusion parameters clearly distinguished abnormal from normal segments for beta reserve (1.13 (0.99) vs 2.22 (1.36), p<0.001) and MBF reserve (1.80 (2.29) vs 3.69 (2.79), p<0.001). The beta reserve cut-off of 1.60 provided the following: AUC, 0.787; sensitivity, 82%; specificity, 66%; LR+, 2.40; and LR-, 0.28. The MBF reserve cut-off of 1.90 provided the following: AUC, 0.779; sensitivity, 73%; specificity, 72%; LR+, 2.69; and LR-, 0.37. MBF reserve had an AUC of 0.773 for the left anterior descending coronary artery, 0.885 for the left circumflex coronary artery and 0.739 for the right coronary artery. CONCLUSIONS: Real-time MCE-derived absolute MBF, beta, and reserve values are feasible and accurate for detecting myocardial perfusion abnormalities as defined by SPECT. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
4. Deep neural network based tissue deconvolution of circulating tumor cell RNA.
- Author
-
Yan F, Jiang L, Ye F, Ping J, Bowley TY, Ness SA, Li CI, Marchetti D, Tang J, and Guo Y
- Subjects
- Humans, Neural Networks, Computer, RNA-Seq, Sequence Analysis, RNA, RNA, Neoplastic Cells, Circulating
- Abstract
Prior research has shown that the deconvolution of cell-free RNA can uncover the tissue origin. The conventional deconvolution approaches rely on constructing a reference tissue-specific gene panel, which cannot capture the inherent variation present in actual data. To address this, we have developed a novel method that utilizes a neural network framework to leverage the entire training dataset. Our approach involved training a model that incorporated 15 distinct tissue types. Through one semi-independent and two complete independent validations, including deconvolution using a semi in silico dataset, deconvolution with a custom normal tissue mixture RNA-seq data, and deconvolution of longitudinal circulating tumor cell RNA-seq (ctcRNA) data from a cancer patient with metastatic tumors, we demonstrate the efficacy and advantages of the deep-learning approach which were exerted by effectively capturing the inherent variability present in the dataset, thus leading to enhanced accuracy. Sensitivity analyses reveal that neural network models are less susceptible to the presence of missing data, making them more suitable for real-world applications. Moreover, by leveraging the concept of organotropism, we applied our approach to trace the migration of circulating tumor cell-derived RNA (ctcRNA) in a cancer patient with metastatic tumors, thereby highlighting the potential clinical significance of early detection of cancer metastasis., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
5. The inflammatory response of human pancreatic cancer samples compared to normal controls.
- Author
-
Brayer KJ, Hanson JA, Cingam S, Martinez C, Ness SA, and Rabinowitz I
- Subjects
- Humans, Pancreas pathology, RNA metabolism, Prognosis, Gene Expression Regulation, Neoplastic, Pancreatic Neoplasms pathology, Carcinoma, Pancreatic Ductal pathology
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a poor prognosis cancer with an aggressive growth profile that is often diagnosed at late stage and that has few curative or therapeutic options. PDAC growth has been linked to alterations in the pancreas microbiome, which could include the presence of the fungus Malassezia. We used RNA-sequencing to compare 14 matched tumor and normal (tumor adjacent) pancreatic cancer samples and found Malassezia RNA in both the PDAC and normal tissues. Although the presence of Malassezia was not correlated with tumor growth, a set of immune- and inflammatory-related genes were up-regulated in the PDAC compared to the normal samples, suggesting that they are involved in tumor progression. Gene set enrichment analysis suggests that activation of the complement cascade pathway and inflammation could be involved in pro PDAC growth., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Brayer et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
6. The immune response to a fungus in pancreatic cancer samples.
- Author
-
Brayer KJ, Hanson JA, Cingam S, Martinez C, Ness SA, and Rabinowitz I
- Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a poor prognosis cancer with an .aggressive growth profile that is often diagnosed at late stage and that has few curative or therapeutic options. PDAC growth has been linked to alterations in the pancreas microbiome, which could include the presence of the fungus Malassezia . We used RNA-sequencing to compare 14 paired tumor and normal (tumor adjacent) pancreatic cancer samples and found Malassezia RNA in both the PDAC and normal tissues. Although the presence of Malassezia was not correlated with tumor growth, a set of immune- and inflammatory-related genes were up-regulated in the PDAC compared to the normal samples, suggesting that they are involved in tumor progression. Gene set enrichment analysis suggests that activation of the complement cascade pathway and inflammation could be involved in pro PDAC growth.
- Published
- 2023
- Full Text
- View/download PDF
7. Dominant Gene Expression Profiles Define Adenoid Cystic Carcinoma (ACC) from Different Tissues: Validation of a Gene Signature Classifier for Poor Survival in Salivary Gland ACC.
- Author
-
Brayer KJ, Kang H, El-Naggar AK, Andreasen S, Homøe P, Kiss K, Mikkelsen L, Heegaard S, Pelaez D, Moeyersoms A, Tse DT, Guo Y, Lee DY, and Ness SA
- Abstract
Adenoid cystic carcinoma (ACC) is an aggressive malignancy that most often arises in salivary or lacrimal glands but can also occur in other tissues. We used optimized RNA-sequencing to analyze the transcriptomes of 113 ACC tumor samples from salivary gland, lacrimal gland, breast or skin. ACC tumors from different organs displayed remarkedly similar transcription profiles, and most harbored translocations in the MYB or MYBL1 genes, which encode oncogenic transcription factors that may induce dramatic genetic and epigenetic changes leading to a dominant 'ACC phenotype'. Further analysis of the 56 salivary gland ACC tumors led to the identification of three distinct groups of patients, based on gene expression profiles, including one group with worse survival. We tested whether this new cohort could be used to validate a biomarker developed previously with a different set of 68 ACC tumor samples. Indeed, a 49-gene classifier developed with the earlier cohort correctly identified 98% of the poor survival patients from the new set, and a 14-gene classifier was almost as accurate. These validated biomarkers form a platform to identify and stratify high-risk ACC patients into clinical trials of targeted therapies for sustained clinical response.
- Published
- 2023
- Full Text
- View/download PDF
8. Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity.
- Author
-
Steinkamp MP, Lagutina I, Brayer KJ, Schultz F, Burke D, Pankratz VS, Adams SF, Hudson LG, Ness SA, and Wandinger-Ness A
- Subjects
- Humans, Mice, Animals, Female, Heterografts, Ascites, Cytokines, Tumor Microenvironment, Peritoneal Cavity, Ovarian Neoplasms therapy
- Abstract
The importance of the immune microenvironment in ovarian cancer progression, metastasis, and response to therapies has become increasingly clear, especially with the new emphasis on immunotherapies. To leverage the power of patient-derived xenograft (PDX) models within a humanized immune microenvironment, three ovarian cancer PDXs were grown in humanized NBSGW (huNBSGW) mice engrafted with human CD34
+ cord blood-derived hematopoietic stem cells. Analysis of cytokine levels in the ascites fluid and identification of infiltrating immune cells in the tumors demonstrated that these humanized PDX (huPDX) established an immune tumor microenvironment similar to what has been reported for patients with ovarian cancer. The lack of human myeloid cell differentiation has been a major setback for humanized mouse models, but our analysis shows that PDX engraftment increases the human myeloid population in the peripheral blood. Analysis of cytokines within the ascites fluid of huPDX revealed high levels of human M-CSF, a key myeloid differentiation factor as well as other elevated cytokines that have previously been identified in ovarian cancer patient ascites fluid including those involved in immune cell differentiation and recruitment. Human tumor-associated macrophages and tumor-infiltrating lymphocytes were detected within the tumors of humanized mice, demonstrating immune cell recruitment to tumors. Comparison of the three huPDX revealed certain differences in cytokine signatures and in the extent of immune cell recruitment. Our studies show that huNBSGW PDX models reconstitute important aspects of the ovarian cancer immune tumor microenvironment, which may recommend these models for preclinical therapeutic trials., Significance: huPDX models are ideal preclinical models for testing novel therapies. They reflect the genetic heterogeneity of the patient population, enhance human myeloid differentiation, and recruit immune cells to the tumor microenvironment., (© 2023 The Authors; Published by the American Association for Cancer Research.)- Published
- 2023
- Full Text
- View/download PDF
9. Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N -of-1 clinical trial.
- Author
-
Shaheen MF, Tse JY, Sokol ES, Masterson M, Bansal P, Rabinowitz I, Tarleton CA, Dobroff AS, Smith TL, Bocklage TJ, Mannakee BK, Gutenkunst RN, Bischoff J, Ness SA, Riedlinger GM, Groisberg R, Pasqualini R, Ganesan S, and Arap W
- Subjects
- Class Ia Phosphatidylinositol 3-Kinase metabolism, Endothelial Cells drug effects, Endothelial Cells metabolism, Genomics, High-Throughput Nucleotide Sequencing, Humans, Immunohistochemistry, Mutation, Sequence Analysis, DNA, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Class I Phosphatidylinositol 3-Kinases antagonists & inhibitors, Class I Phosphatidylinositol 3-Kinases genetics, Class I Phosphatidylinositol 3-Kinases metabolism, GTP Phosphohydrolases genetics, Lymphangioma drug therapy, Lymphangioma genetics, Lymphatic Abnormalities drug therapy, Lymphatic Abnormalities genetics, Membrane Proteins genetics, Thiazoles pharmacology, Thiazoles therapeutic use
- Abstract
Background: Lymphatic malformations (LMs) often pose treatment challenges due to a large size or a critical location that could lead to disfigurement, and there are no standardized treatment approaches for either refractory or unresectable cases., Methods: We examined the genomic landscape of a patient cohort of LMs ( n = 30 cases) that underwent comprehensive genomic profiling using a large-panel next-generation sequencing assay. Immunohistochemical analyses were completed in parallel., Results: These LMs had low mutational burden with hotspot PIK3CA mutations ( n = 20) and NRAS ( n = 5) mutations being most frequent, and mutually exclusive. All LM cases with Kaposi sarcoma-like (kaposiform) histology had NRAS mutations. One index patient presented with subacute abdominal pain and was diagnosed with a large retroperitoneal LM harboring a somatic PIK3CA gain-of-function mutation (H1047R). The patient achieved a rapid and durable radiologic complete response, as defined in RECIST1.1, to the PI3Kα inhibitor alpelisib within the context of a personalized N -of-1 clinical trial (NCT03941782). In translational correlative studies, canonical PI3Kα pathway activation was confirmed by immunohistochemistry and human LM-derived lymphatic endothelial cells carrying an allele with an activating mutation at the same locus were sensitive to alpelisib treatment in vitro, which was demonstrated by a concentration-dependent drop in measurable impedance, an assessment of cell status., Conclusions: Our findings establish that LM patients with conventional or kaposiform histology have distinct, yet targetable, driver mutations., Funding: R.P. and W.A. are supported by awards from the Levy-Longenbaugh Fund. S.G. is supported by awards from the Hugs for Brady Foundation. This work has been funded in part by the NCI Cancer Center Support Grants (CCSG; P30) to the University of Arizona Cancer Center (CA023074), the University of New Mexico Comprehensive Cancer Center (CA118100), and the Rutgers Cancer Institute of New Jersey (CA072720). B.K.M. was supported by National Science Foundation via Graduate Research Fellowship DGE-1143953., Clinical Trial Number: NCT03941782., Competing Interests: MS reports personal fees from Illumina, BMS, and Qiagen (outside of the submitted work). The author has no other competing interests to declare, JT, ES is an employee of Foundation Medicine, Inc, a wholly owned subsidiary of Roche, and owns equity in Roche. The author has no other competing interests to declare, MM, PB, IR, CT, AD, TS, TB, RG, JB, SN, GR No competing interests declared, BM is an employee of Foundation Medicine, Inc, a wholly owned subsidiary of Roche, and owns equity in Roche, RG reports research funding/grant support for clinical trials (to his institution) from Regeneron, BMS, Merck/EMD Serano, Amgen, Roche/Genentech, Philogen; consulting/advisory board fees from Regeneron; and speaker fees for Deciphera (all outside of the submitted work). These arrangements are managed in accordance with the established institutional conflict of interest policies of Rutgers, The State University of New Jersey. The author has no other competing interests to declare, RP, WA Reviewing editor, eLife, SG has consulting agreements with Merck, Roche, Novartis, Foundation Medicine, EQRX, Foghorn Therapeutics, Silagene, and KayoThera and owns equity in Silagene; his spouse is an employee of Merck and owns equity in Merck (all outside of the submitted work). These arrangements are managed in accordance with the established institutional conflict of interest policies of Rutgers, The State University of New Jersey. The author has no other competing interests to declare, (© 2022, Shaheen, Tse et al.)
- Published
- 2022
- Full Text
- View/download PDF
10. Two-step mixed model approach to analyzing differential alternative RNA splicing.
- Author
-
Luo L, Kang H, Li X, Ness SA, and Stidley CA
- Subjects
- Algorithms, Child, Gene Expression Regulation, Neoplastic, Humans, Linear Models, Models, Genetic, RNA, Messenger genetics, Sequence Analysis, RNA methods, Exome Sequencing, Alternative Splicing, Carcinoma, Adenoid Cystic genetics, Gene Expression Profiling methods, Gene Regulatory Networks, Leukemia, Myeloid, Acute genetics
- Abstract
Changes in gene expression can correlate with poor disease outcomes in two ways: through changes in relative transcript levels or through alternative RNA splicing leading to changes in relative abundance of individual transcript isoforms. The objective of this research is to develop new statistical methods in detecting and analyzing both differentially expressed and spliced isoforms, which appropriately account for the dependence between isoforms and multiple testing corrections for the multi-dimensional structure of at both the gene- and isoform- level. We developed a linear mixed effects model-based approach for analyzing the complex alternative RNA splicing regulation patterns detected by whole-transcriptome RNA-sequencing technologies. This approach thoroughly characterizes and differentiates three types of genes related to alternative RNA splicing events with distinct differential expression/splicing patterns. We applied the concept of appropriately controlling for the gene-level overall false discovery rate (OFDR) in this multi-dimensional alternative RNA splicing analysis utilizing a two-step hierarchical hypothesis testing framework. In the initial screening test we identify genes that have differentially expressed or spliced isoforms; in the subsequent confirmatory testing stage we examine only the isoforms for genes that have passed the screening tests. Comparisons with other methods through application to a whole transcriptome RNA-Seq study of adenoid cystic carcinoma and extensive simulation studies have demonstrated the advantages and improved performances of our method. Our proposed method appropriately controls the gene-level OFDR, maintains statistical power, and is flexible to incorporate advanced experimental designs., Competing Interests: NO authors have competing interests
- Published
- 2020
- Full Text
- View/download PDF
11. Oncogenic Orphan Nuclear Receptor NR4A3 Interacts and Cooperates with MYB in Acinic Cell Carcinoma.
- Author
-
Lee DY, Brayer KJ, Mitani Y, Burns EA, Rao PH, Bell D, Williams MD, Ferrarotto R, Pytynia KB, El-Naggar AK, and Ness SA
- Abstract
Acinic cell carcinoma (AcCC) is a morphologically distinctive salivary gland malignancy often associated with chromosome rearrangements leading to overexpression of the NR4A3 transcription factor. However, little is known about how NR4A3 contributes to AcCC biology. Detailed RNA-sequencing of 21 archived AcCC samples revealed fusion reads arising from recurrent t(4;9), t(9;12), t(8;9) or t(2;4) chromosomal translocations, which positioned highly active enhancers adjacent to the promoter of the NR4A3 gene or the closely related NR4A2 gene, resulting in their aberrant overexpression. Transcriptome analyses revealed several distinct subgroups of AcCC tumors, including a subgroup that overexpressed both NR4A3 and MSANTD3 . A poor survival subset of the tumors with high-grade transformation expressed NR4A3 and POMC as well as MYB , an oncogene that is the major driver in a different type of salivary gland tumor, adenoid cystic carcinoma. The combination of NR4A3 and MYB showed cooperativity in regulating a distinct set of genes. In addition, the ligand binding domain of NR4A3 directly bound the Myb DNA binding domain. Transformation assays indicated that, while overexpressed NR4A3 was sufficient to generate transformed colonies, the combination of NR4A3 plus Myb was more potent, leading to anchorage-independent growth and increased cellular invasiveness. The results confirm that NR4A3 and NR4A2 are the main driver genes of AcCC and suggest that concurrent overexpression of NR4A3 and MYB defines a subset of AcCC patients with high-grade transformation that display exceptionally poor outcome.
- Published
- 2020
- Full Text
- View/download PDF
12. N-Terminal Truncated Myb with New Transcriptional Activity Produced Through Use of an Alternative MYB Promoter in Salivary Gland Adenoid Cystic Carcinoma.
- Author
-
Frerich CA, Sedam HN, Kang H, Mitani Y, El-Naggar AK, and Ness SA
- Abstract
Adenoid cystic carcinoma (ACC) is an aggressive salivary gland tumor that frequently displays perineural invasion and is often associated with translocations or overexpression of the MYB oncogene. Detailed analyses of MYB transcripts from ACC patient samples revealed that ACC tumors utilize an alternative MYB promoter, which is rarely used in normal cells or other tumor types. The alternative promoter transcripts produce N-terminally truncated Myb proteins lacking a highly conserved and phosphorylated domain, which includes the pS11 epitope that is frequently used to detect Myb proteins. In RNA-seq assays, Myb isoforms lacking the N-terminal domain displayed unique transcriptional activities, regulating many genes differently than full-length Myb. Thus, a regulatory pathway unique to ACC activates the alternative MYB promoter, leading to the production of a truncated Myb protein with altered transcriptional activities. This could provide new therapeutic opportunities for ACC patients., Competing Interests: The authors declare no conflicts of interest. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- Published
- 2019
- Full Text
- View/download PDF
13. Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
- Author
-
Greenbaum A, Martin DR, Bocklage T, Lee JH, Ness SA, and Rajput A
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma mortality, Alleles, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biopsy, DNA Mutational Analysis, Female, Genetic Heterogeneity, High-Throughput Nucleotide Sequencing, Humans, Male, Mutation, Neoplasm Staging, Patient Selection, Proctectomy, Prognosis, Prospective Studies, Rectal Neoplasms genetics, Rectal Neoplasms mortality, Rectum pathology, Rectum surgery, Survival Analysis, Treatment Outcome, Adenocarcinoma therapy, Biomarkers, Tumor genetics, Chemoradiotherapy, Adjuvant methods, Neoadjuvant Therapy methods, Rectal Neoplasms therapy
- Abstract
Background: Neoadjuvant chemoradiotherapy (nCRT) is the standard of care for locally advanced adenocarcinoma of the rectum, but it is currently unknown which patients have disease that will respond. This study tested the correlation between response to nCRT and intratumoral heterogeneity using next-generation sequencing assays., Patients and Methods: DNA was extracted from formalin-fixed, paraffin-embedded biopsy samples from a cohort of patients with locally advanced rectal adenocarcinoma (T3/4 or N1/2 disease) who received nCRT. High read-depth sequencing of > 400 cancer-relevant genes was performed. Tumor mutations and variant allele frequencies were used to calculate mutant-allele tumor heterogeneity (MATH) scores as measures of intratumoral heterogeneity. Response to nCRT was pathologically scored after surgical resection., Results: Biopsy samples from 21 patient tumors were analyzed. Eight patients had disease noted to have complete response, 2 moderate, 4 minimal, and 7 poor. Higher MATH scores correlated with poorer response to treatment, demonstrating significantly increased tumor heterogeneity compared to complete response (P = .039)., Conclusion: The application of MATH scores as a measure of tumor heterogeneity may provide a useful biomarker for treatment response in locally advanced rectal cancer., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
14. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
- Author
-
Sharma ND, Nickl CK, Kang H, Ornatowski W, Brown R, Ness SA, Loh ML, Mullighan CG, Winter SS, Hunger SP, Cannon JL, and Matlawska-Wasowska K
- Subjects
- Animals, Cell Line, Cell Line, Tumor, DNA (Cytosine-5-)-Methyltransferases genetics, DNA (Cytosine-5-)-Methyltransferases metabolism, DNA Methyltransferase 3A, Disease Progression, Gene Expression Profiling, Humans, Janus Kinases metabolism, Jurkat Cells, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma metabolism, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma pathology, RNAi Therapeutics methods, Receptors, Cytokine genetics, Receptors, Cytokine metabolism, STAT Transcription Factors metabolism, Signal Transduction genetics, Suppressor of Cytokine Signaling Proteins metabolism, Survival Analysis, Xenograft Model Antitumor Assays methods, Epigenesis, Genetic, Janus Kinases genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics, STAT Transcription Factors genetics, Suppressor of Cytokine Signaling Proteins genetics
- Abstract
Activating mutations in cytokine receptors and transcriptional regulators govern aberrant signal transduction in T-cell lineage acute lymphoblastic leukemia (T-ALL). However, the roles played by suppressors of cytokine signaling remain incompletely understood. We examined the regulatory roles of suppressor of cytokine signaling 5 (SOCS5) in T-ALL cellular signaling networks and leukemia progression. We found that SOCS5 was differentially expressed in primary T-ALL and its expression levels were lowered in HOXA-deregulated leukemia harboring KMT2A gene rearrangements. Here, we report that SOCS5 expression is epigenetically regulated by DNA methyltransferase-3A-mediated DNA methylation and methyl CpG binding protein-2-mediated histone deacetylation. We show that SOCS5 negatively regulates T-ALL cell growth and cell cycle progression but has no effect on apoptotic cell death. Mechanistically, SOCS5 silencing induces activation of JAK-STAT signaling, and negatively regulates interleukin-7 and interleukin-4 receptors. Using a human T-ALL murine xenograft model, we show that genetic inactivation of SOCS5 accelerates leukemia engraftment and progression, and leukemia burden. We postulate that SOCS5 is epigenetically deregulated in T-ALL and serves as an important regulator of T-ALL cell proliferation and leukemic progression. Our results link aberrant downregulation of SOCS5 expression to the enhanced activation of the JAK-STAT and cytokine receptor-signaling cascade in T-ALL., (© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Published
- 2019
- Full Text
- View/download PDF
15. Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes.
- Author
-
Frerich CA, Brayer KJ, Painter BM, Kang H, Mitani Y, El-Naggar AK, and Ness SA
- Abstract
The relative rarity of salivary gland adenoid cystic carcinoma (ACC) and its slow growing yet aggressive nature has complicated the development of molecular markers for patient stratification. To analyze molecular differences linked to the protracted disease course of ACC and metastases that form 5 or more years after diagnosis, detailed RNA-sequencing (RNA-seq) analysis was performed on 68 ACC tumor samples, starting with archived, formalin-fixed paraffin-embedded (FFPE) samples up to 25 years old, so that clinical outcomes were available. A statistical peak-finding approach was used to classify the tumors that expressed MYB or MYBL1 , which had overlapping gene expression signatures, from a group that expressed neither oncogene and displayed a unique phenotype. Expression of MYB or MYBL1 was closely correlated to the expression of the SOX4 and EN1 genes, suggesting that they are direct targets of Myb proteins in ACC tumors. Unsupervised hierarchical clustering identified a subgroup of approximately 20% of patients with exceptionally poor overall survival (median less than 30 months) and a unique gene expression signature resembling embryonic stem cells. The results provide a strategy for stratifying ACC patients and identifying the high-risk, poor-outcome group that are candidates for personalized therapies., Competing Interests: CONFLICTS OF INTEREST No potential conflicts of interest for any author.
- Published
- 2017
- Full Text
- View/download PDF
16. Mutant-Allele Tumor Heterogeneity Scores Correlate With Risk of Metastases in Colon Cancer.
- Author
-
Rajput A, Bocklage T, Greenbaum A, Lee JH, and Ness SA
- Subjects
- Alleles, DNA Mutational Analysis, Humans, Neoplasm Invasiveness pathology, Risk Factors, Colonic Neoplasms genetics, Colonic Neoplasms pathology, Neoplasm Invasiveness genetics
- Abstract
Background: Colorectal cancer is a leading cause of cancer-related mortality, has a very broad mutational spectrum, and there is no clinically available biomarker that can predict which patients with stage II or stage III colorectal cancer will develop metastatic disease., Patients and Methods: We used a targeted next-generation sequencing approach to analyze the mutational spectra in stage II and III colon cancer patient samples., Results: Amidst a broad range of acquired mutations and variants, we found evidence of tumor heterogeneity that distinguished the tumors in different groups. When heterogeneity was quantified using the Mutant-Allele Tumor Heterogeneity (MATH) score, there was a strong correlation between higher MATH score and risk of metastases., Conclusions: Measures of tumor heterogeneity might be useful biomarkers for identifying patients with colon cancer who are at risk of developing metastases. This might allow for more specific, tailored follow-up and adjuvant therapies after standard surgery., (Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
17. Editorial: Targeting MYB Oncogene Expression in Adenoid Cystic Carcinoma.
- Author
-
Ness SA
- Subjects
- Biomarkers, Tumor, Humans, Oncogene Proteins, Fusion genetics, Carcinoma, Adenoid Cystic genetics, Genes, myb
- Published
- 2017
- Full Text
- View/download PDF
18. Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.
- Author
-
Mayfield JR, Czuchlewski DR, Gale JM, Matlawska-Wasowska K, Vasef MA, Nickl C, Pickett G, Ness SA, and Winter SS
- Subjects
- Adolescent, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Fusion Proteins, bcr-abl genetics, Humans, Mutation genetics, Neoplasm, Residual drug therapy, Nitriles, Pyrimidines, Stem Cell Transplantation, Treatment Outcome, Janus Kinase 2 antagonists & inhibitors, Janus Kinase 2 genetics, Molecular Targeted Therapy methods, Precision Medicine methods, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Pyrazoles therapeutic use
- Abstract
A 17-year-old girl with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with persistent minimal residual disease (MRD) who underwent standard chemotherapy was found to have a BCR-ABL1-like gene expression pattern. Genome sequencing revealed a JAK2 mutation not previously described in BCP-ALL and a potential therapeutic target. Due to concern for an on-therapy relapse, the JAK2 inhibitor ruxolitinib was incorporated into a modified chemotherapy backbone to achieve complete remission prior to stem cell transplant. Treatment was well tolerated and she had undetectable MRD prior to a matched allogeneic stem cell transplant and remained in remission at day +100., (© 2016 Wiley Periodicals, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
19. Optimized approach for Ion Proton RNA sequencing reveals details of RNA splicing and editing features of the transcriptome.
- Author
-
Brown RB, Madrid NJ, Suzuki H, and Ness SA
- Subjects
- Antigens, CD34 metabolism, Humans, Jurkat Cells, Protein Isoforms, RNA Editing, RNA Splicing, Sequence Analysis, RNA methods, Transcriptome
- Abstract
RNA-sequencing (RNA-seq) has become the standard method for unbiased analysis of gene expression but also provides access to more complex transcriptome features, including alternative RNA splicing, RNA editing, and even detection of fusion transcripts formed through chromosomal translocations. However, differences in library methods can adversely affect the ability to recover these different types of transcriptome data. For example, some methods have bias for one end of transcripts or rely on low-efficiency steps that limit the complexity of the resulting library, making detection of rare transcripts less likely. We tested several commonly used methods of RNA-seq library preparation and found vast differences in the detection of advanced transcriptome features, such as alternatively spliced isoforms and RNA editing sites. By comparing several different protocols available for the Ion Proton sequencer and by utilizing detailed bioinformatics analysis tools, we were able to develop an optimized random primer based RNA-seq technique that is reliable at uncovering rare transcript isoforms and RNA editing features, as well as fusion reads from oncogenic chromosome rearrangements. The combination of optimized libraries and rapid Ion Proton sequencing provides a powerful platform for the transcriptome analysis of research and clinical samples.
- Published
- 2017
- Full Text
- View/download PDF
20. Distinct histone methylation and transcription profiles are established during the development of cellular quiescence in yeast.
- Author
-
Young CP, Hillyer C, Hokamp K, Fitzpatrick DJ, Konstantinov NK, Welty JS, Ness SA, Werner-Washburne M, Fleming AB, and Osley MA
- Subjects
- Genome-Wide Association Study, Genomics methods, Methylation, Mutation, Protein Binding, RNA Polymerase II metabolism, Yeasts metabolism, Gene Expression Regulation, Fungal, Histones metabolism, Resting Phase, Cell Cycle genetics, Transcriptome, Yeasts genetics
- Abstract
Background: Quiescent cells have a low level of gene activity compared to growing cells. Using a yeast model for cellular quiescence, we defined the genome-wide profiles of three species of histone methylation associated with active transcription between growing and quiescent cells, and correlated these profiles with the presence of RNA polymerase II and transcripts., Results: Quiescent cells retained histone methylations normally associated with transcriptionally active chromatin and had many transcripts in common with growing cells. Quiescent cells also contained significant levels of RNA polymerase II, but only low levels of the canonical initiating and elongating forms of the polymerase. The RNA polymerase II associated with genes in quiescent cells displayed a distinct occupancy profile compared to its pattern of occupancy across genes in actively growing cells. Although transcription is generally repressed in quiescent cells, analysis of individual genes identified a period of active transcription during the development of quiescence., Conclusions: The data suggest that the transcript profile and histone methylation marks in quiescent cells were established both in growing cells and during the development of quiescence and then retained in these cells. Together, this might ensure that quiescent cells can rapidly adapt to a changing environment to resume growth.
- Published
- 2017
- Full Text
- View/download PDF
21. MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study.
- Author
-
Matlawska-Wasowska K, Kang H, Devidas M, Wen J, Harvey RC, Nickl CK, Ness SA, Rusch M, Li Y, Onozawa M, Martinez C, Wood BL, Asselin BL, Chen IM, Roberts KG, Baruchel A, Soulier J, Dombret H, Zhang J, Larson RS, Raetz EA, Carroll WL, Winick NJ, Aplan PD, Loh ML, Mullighan CG, Hunger SP, Heerema NA, Carroll AJ, Dunsmore KP, and Winter SS
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Disease-Free Survival, Female, Gene Rearrangement, Humans, Male, Neoplasm Recurrence, Local mortality, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma mortality, Prognosis, Retrospective Studies, Cell Lineage, Drug Resistance, Neoplasm genetics, Histone-Lysine N-Methyltransferase genetics, Homeodomain Proteins genetics, Myeloid-Lymphoid Leukemia Protein genetics, Neoplasm Recurrence, Local genetics, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma genetics
- Abstract
Competing Interests: The authors have no financial conflicts to disclose.
- Published
- 2016
- Full Text
- View/download PDF
22. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.
- Author
-
Brayer KJ, Frerich CA, Kang H, and Ness SA
- Subjects
- DNA-Binding Proteins genetics, Humans, NFI Transcription Factors genetics, Proto-Oncogene Mas, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-myb genetics, Sequence Analysis, RNA methods, Trans-Activators genetics, Translocation, Genetic, Carcinoma, Adenoid Cystic genetics, Oncogene Proteins, Fusion genetics, Salivary Gland Neoplasms genetics, Transcription Factors genetics
- Abstract
Unlabelled: Adenoid cystic carcinoma (ACC), the second most common malignancy of salivary glands, is a rare tumor with a bleak prognosis for which therapeutic targets are unavailable. We used RNA sequencing (RNA-seq) to analyze low-quality RNA from archival, formaldehyde-fixed, paraffin-embedded samples. In addition to detecting the most common ACC translocation, t(6;9) fusing the MYB proto-oncogene to NFIB, we also detected previously unknown t(8;9) and t(8;14) translocations fusing the MYBL1 gene to the NFIB and RAD51B genes, respectively. RNA-seq provided information about gene fusions, alternative RNA splicing, and gene expression signatures. Interestingly, tumors with MYB and MYBL1 translocations displayed similar gene expression profiles, and the combined MYB and MYBL1 expression correlated with outcome, suggesting that the related MYB proteins are interchangeable oncogenic drivers in ACC. Our results provide important details about the biology of ACC and illustrate how archival tissue samples can be used for detailed molecular analyses of rare tumors., Significance: Using RNA-seq to perform whole-transcriptome analysis of archival ACC tumor samples, we identified novel, recurrent gene fusions, detected alternative RNA splicing, and established gene expression signatures that provide detailed information about the biology of ACC tumors., (©2015 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
23. Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis.
- Author
-
George OL and Ness SA
- Abstract
This review summarizes the mechanisms that control the activity of the c-Myb transcription factor in normal cells and tumors, and discusses how c-Myb plays a role in the regulation of the cell cycle. Oncogenic versions of c-Myb contribute to the development of leukemias and solid tumors such as adenoid cystic carcinoma, breast cancer and colon cancer. The activity and specificity of the c-Myb protein seems to be controlled through changes in protein-protein interactions, so understanding how it is regulated could lead to the development of novel therapeutic strategies.
- Published
- 2014
- Full Text
- View/download PDF
24. Transdiaphragmatic hepatic and pulmonary abscess attributed to ileal diverticulitis in a horse.
- Author
-
Ruby R, Buckles E, Pinn T, Ness SA, Yeager AE, and Ainsworth DM
- Subjects
- Abscess diagnostic imaging, Abscess microbiology, Abscess pathology, Animals, Diverticulitis diagnostic imaging, Diverticulitis microbiology, Diverticulitis pathology, Fatal Outcome, Female, Histocytochemistry veterinary, Horse Diseases diagnostic imaging, Horse Diseases microbiology, Horses, Liver Abscess diagnostic imaging, Liver Abscess immunology, Liver Abscess pathology, Lung Abscess diagnostic imaging, Lung Abscess microbiology, Lung Abscess pathology, Radiography, Abscess veterinary, Diverticulitis veterinary, Horse Diseases pathology, Liver Abscess veterinary, Lung Abscess veterinary
- Published
- 2013
- Full Text
- View/download PDF
25. RNA editing events in mitochondrial genes by ultra-deep sequencing methods: a comparison of cytoplasmic male sterile, fertile and restored genotypes in cotton.
- Author
-
Suzuki H, Yu J, Ness SA, O'Connell MA, and Zhang J
- Subjects
- DNA, Mitochondrial genetics, DNA, Mitochondrial metabolism, DNA, Plant genetics, DNA, Plant metabolism, Gossypium genetics, RNA genetics, RNA, Mitochondrial, RNA, Plant genetics, Gossypium metabolism, Plant Infertility physiology, RNA metabolism, RNA Editing physiology, RNA, Plant metabolism
- Abstract
Cytoplasmic male sterility (CMS) is a maternally inherited trait resulting in failure to produce functional pollen and is widely used in the production of hybrid seed. Improper RNA editing is implicated as the molecular basis for some CMS systems. However, the mechanism of CMS in cotton is unknown. This study compared RNA editing events in eight mitochondrial genes (atp1, 4, 6, 8, 9, and cox1, 2, 3) among three lines (maintainer B, CMS A, and restorer R). These events were quantified by ultra-deep sequencing of mitochondrial transcripts and sequencing of cloned versions of these genes as cDNAs. A comparison of genomic PCR and RT-PCR products detected 72 editing sites in coding sequences in the eight genes and four partial editing sites in the 3'-untranslated region of atp6. The most frequent alteration (61.4 %) resulted in changes of hydrophilic amino acids to hydrophobic amino acids and the most common alteration was proline (P) to leucine (L) (26.7 %). In atp6, RNA editing created a stop codon from a glutamine in the genomic sequence. Statistical analysis of the frequencies of RNA editing events detected differences between mtDNA genes, but no differences between cotton cytoplasms that could account for the CMS phenotype or restoration. This study represents the first work to use next-generation sequencing to identify RNA editing positions and efficiency, and possible association with CMS and restoration in plants.
- Published
- 2013
- Full Text
- View/download PDF
26. Adult human CD133/1(+) kidney cells isolated from papilla integrate into developing kidney tubules.
- Author
-
Ward HH, Romero E, Welford A, Pickett G, Bacallao R, Gattone VH 2nd, Ness SA, Wandinger-Ness A, and Roitbak T
- Subjects
- AC133 Antigen, Adult Stem Cells transplantation, Animals, Cell Differentiation, Cell Separation, Coculture Techniques, Colony-Forming Units Assay, Humans, Mice, Organ Culture Techniques, Polycystic Kidney, Autosomal Dominant therapy, Adult Stem Cells cytology, Adult Stem Cells immunology, Antigens, CD metabolism, Glycoproteins metabolism, Kidney Medulla cytology, Kidney Tubules cytology, Kidney Tubules growth & development, Peptides metabolism
- Abstract
Approximately 60,000 patients in the United States are waiting for a kidney transplant due to genetic, immunologic and environmentally caused kidney failure. Adult human renal stem cells could offer opportunities for autologous transplant and repair of damaged organs. Current data suggest that there are multiple progenitor types in the kidney with distinct localizations. In the present study, we characterize cells derived from human kidney papilla and show their capacity for tubulogenesis. In situ, nestin(+) and CD133/1(+) cells were found extensively intercalated between tubular epithelia in the loops of Henle of renal papilla, but not of the cortex. Populations of primary cells from the renal cortex and renal papilla were isolated by enzymatic digestion from human kidneys unsuited for transplant and immuno-enriched for CD133/1(+) cells. Isolated CD133/1(+) papillary cells were positive for nestin, as well as several human embryonic stem cell markers (SSEA4, Nanog, SOX2, and OCT4/POU5F1) and could be triggered to adopt tubular epithelial and neuronal-like phenotypes. Isolated papillary cells exhibited morphologic plasticity upon modulation of culture conditions and inhibition of asymmetric cell division. Labeled papillary cells readily associated with cortical tubular epithelia in co-culture and 3-dimensional collagen gel cultures. Heterologous organ culture demonstrated that CD133/1(+) progenitors from the papilla and cortex became integrated into developing kidney tubules. Tubular epithelia did not participate in tubulogenesis. Human renal papilla harbor cells with the hallmarks of adult kidney stem/progenitor cells that can be amplified and phenotypically modulated in culture while retaining the capacity to form new kidney tubules. This article is part of a Special Issue entitled: Polycystic Kidney Disease., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
27. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
- Author
-
Meng X, Matlawska-Wasowska K, Girodon F, Mazel T, Willman CL, Atlas S, Chen IM, Harvey RC, Hunger SP, Ness SA, Winter SS, and Wilson BS
- Subjects
- Amyloid Precursor Protein Secretases metabolism, Animals, Antineoplastic Agents therapeutic use, B-Lymphocytes drug effects, B-Lymphocytes enzymology, Cell Line, Tumor drug effects, Cell Line, Tumor enzymology, Child, Cohort Studies, Gene Expression Regulation, Leukemic drug effects, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Neoplasm Proteins drug effects, Neoplasm Proteins metabolism, Oligopeptides therapeutic use, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology, Protease Inhibitors therapeutic use, Proteasome Endopeptidase Complex drug effects, RNA, Messenger metabolism, RNA, Neoplasm metabolism, Receptors, Notch genetics, Risk, Specific Pathogen-Free Organisms, Transcription, Genetic drug effects, Xenograft Model Antitumor Assays, Young Adult, Amyloid Precursor Protein Secretases antagonists & inhibitors, Antineoplastic Agents pharmacology, Apoptosis drug effects, Neoplasm Proteins antagonists & inhibitors, Oligopeptides pharmacology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma enzymology, Protease Inhibitors pharmacology, Proteasome Inhibitors, Receptors, Notch physiology
- Abstract
Gamma secretase inhibitors (GSIs) comprise a growing class of compounds that interfere with the membrane-bound Notch signaling protein and its downstream intra-nuclear transcriptional targets. As GSI-I (Z-LLNle-CHO) is also a derivative of a widely used proteosome inhibitor MG-132, we hypothesized that this compound might be active in precursor-B acute lymphoblastic leukemia (ALL) cell lines and patient samples. We found that GSI-I treatment of precursor-B ALL blasts induced apoptotic cell death within 18-24 h. With confirmation using RNA and protein analyses, GSI-I blocked nuclear accumulation of cleaved Notch1 and Notch2, and inhibited Notch targets Hey2 and Myc. Microarray analyses of 207 children with high-risk precursor-B ALL demonstrate that Notch pathway expression is a common feature of these neoplasms. However, microarray studies also implicated additional transcriptional targets in GSI-I-dependent cell death, including genes in the unfolded protein response, nuclear factor-κB and p53 pathways. Z-LLNle-CHO blocks both γ-secretase and proteosome activity, inducing more robust cell death in precursor-B ALL cells than either proteosome-selective or γ-secretase-selective inhibitors alone. Using Z-LLNle-CHO in a nonobese diabetes/severe combined immunodeficiency (NOD/SCID) precursor-B ALL xenograft model, we found that GSI-I alone delayed or prevented engraftment of B-lymphoblasts in 50% of the animals comprising the experimental group, suggesting that this compound is worthy of additional testing.
- Published
- 2011
- Full Text
- View/download PDF
28. Dramatic repositioning of c-Myb to different promoters during the cell cycle observed by combining cell sorting with chromatin immunoprecipitation.
- Author
-
Quintana AM, Zhou YE, Pena JJ, O'Rourke JP, and Ness SA
- Subjects
- Antineoplastic Agents pharmacology, Cell Cycle drug effects, Cells, Cultured, Chromatin drug effects, Chromatin genetics, Combinatorial Chemistry Techniques methods, Gene Expression Regulation genetics, Gene Expression Regulation physiology, Humans, Hydroxyurea pharmacology, Jurkat Cells, Nocodazole pharmacology, Protein Binding drug effects, Protein Binding physiology, Cell Cycle genetics, Chromatin Immunoprecipitation methods, Flow Cytometry methods, Promoter Regions, Genetic drug effects, Proto-Oncogene Proteins c-myb metabolism
- Abstract
The c-Myb transcription factor is a critical regulator of proliferation and stem cell differentiation, and mutated alleles of c-Myb are oncogenic, but little is known about changes in c-Myb activity during the cell cycle. To map the association of c-Myb with specific target genes during the cell cycle, we developed a novel Fix-Sort-ChIP approach, in which asynchronously growing cells were fixed with formaldehyde, stained with Hoechst 33342 and separated into different cell cycle fractions by flow sorting, then processed for chromatin immunoprecipitation (ChIP) assays. We found that c-Myb actively repositions, binding to some genes only in specific cell cycle phases. In addition, the specificity of c-Myb is dramatically different in small subpopulations of cells, for example cells in the G2/M phase of the cell cycle, than in the bulk population. The repositioning of c-Myb during the cell cycle is not due to changes in its expression and also occurs with ectopically expressed, epitope-tagged versions of c-Myb. The repositioning occurs in established cell lines, in primary human CD34+ hematopoietic progenitors and in primary human acute myeloid leukemia cells. The combination of fixation, sorting and ChIP analysis sheds new light on the dynamic nature of gene regulation during the cell cycle and provides a new type of tool for the analysis of gene regulation in small subsets of cells, such as cells in a specific phase of the cell cycle.
- Published
- 2011
- Full Text
- View/download PDF
29. Identification and regulation of c-Myb target genes in MCF-7 cells.
- Author
-
Quintana AM, Liu F, O'Rourke JP, and Ness SA
- Subjects
- Blotting, Western, Breast Neoplasms genetics, Breast Neoplasms metabolism, Breast Neoplasms pathology, Cell Line, Tumor, Chromatin Immunoprecipitation, Estradiol pharmacology, Estrogens pharmacology, Female, Gene Expression Regulation, Neoplastic drug effects, Humans, Kruppel-Like Factor 4, Protein Binding drug effects, RNA Interference, Receptors, CXCR4 genetics, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Regulation, Neoplastic genetics, Promoter Regions, Genetic genetics, Proto-Oncogene Proteins c-myb genetics, Proto-Oncogene Proteins c-myb metabolism
- Abstract
Background: The c-Myb transcription factor regulates differentiation and proliferation in hematopoietic cells, stem cells and epithelial cells. Although oncogenic versions of c-Myb were first associated with leukemias, over expression or rearrangement of the c-myb gene is common in several types of solid tumors, including breast cancers. Expression of the c-myb gene in human breast cancer cells is dependent on estrogen stimulation, but little is known about the activities of the c-Myb protein or what genes it regulates in estrogen-stimulated cells., Methods: We used chromatin immunoprecipitation coupled with whole genome promoter tiling microarrays to identify endogenous c-Myb target genes in human MCF-7 breast cancer cells and characterized the activity of c-Myb at a panel of target genes during different stages of estrogen deprivation and stimulation., Results: By using different antibodies and different growth conditions, the c-Myb protein was found associated with over 10,000 promoters in MCF-7 cells, including many genes that encode cell cycle regulators or transcription factors and more than 60 genes that encode microRNAs. Several previously identified c-Myb target genes were identified, including CCNB1, MYC and CXCR4 and novel targets such as JUN, KLF4, NANOG and SND1. By studying a panel of these targets to validate the results, we found that estradiol stimulation triggered the association of c-Myb with promoters and that association correlated with increased target gene expression. We studied one target gene, CXCR4, in detail, showing that c-Myb associated with the CXCR4 gene promoter and activated a CXCR4 reporter gene in transfection assays., Conclusions: Our results show that c-Myb associates with a surprisingly large number of promoters in human cells. The results also suggest that estradiol stimulation leads to large-scale, genome-wide changes in c-Myb activity and subsequent changes in gene expression in human breast cancer cells.
- Published
- 2011
- Full Text
- View/download PDF
30. Single molecule analysis of c-myb alternative splicing reveals novel classifiers for precursor B-ALL.
- Author
-
Zhou YE, O'Rourke JP, Edwards JS, and Ness SA
- Subjects
- Biomarkers, Tumor genetics, Cell Line, Tumor, Child, Exons genetics, Humans, RNA, Messenger genetics, RNA, Messenger metabolism, Survival Analysis, Alternative Splicing genetics, Polymerase Chain Reaction methods, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma classification, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Proto-Oncogene Proteins c-myb genetics
- Abstract
The c-Myb transcription factor, a key regulator of proliferation and differentiation in hematopoietic and other cell types, has an N-terminal DNA binding domain and a large C-terminal domain responsible for transcriptional activation, negative regulation and determining target gene specificity. Overexpression and rearrangement of the c-myb gene (MYB) has been reported in some patients with leukemias and other types of cancers, implicating activated alleles of c-myb in the development of human tumors. Alternative RNA splicing can produce variants of c-myb with qualitatively distinct transcriptional activities that may be involved in transformation and leukemogenesis. Here, by performing a detailed, single molecule assay we found that c-myb alternative RNA splicing was elevated and much more complex in leukemia samples than in cell lines or CD34+ hematopoietic progenitor cells from normal donors. The results revealed that leukemia samples express more than 60 different c-myb splice variants, most of which have multiple alternative splicing events and were not detectable by conventional microarray or PCR approaches. For example, the single molecule assay detected 21 and 22 splice variants containing the 9B and 9S exons, respectively, most of which encoded unexpected variant forms of c-Myb protein. Furthermore, the detailed analysis identified some splice variants whose expression correlated with poor survival in a small cohort of precursor B-ALL samples. Our findings indicate that single molecule assays can reveal complexities in c-myb alternative splicing that have potential as novel biomarkers and could help explain the role of c-Myb variants in the development of human leukemia.
- Published
- 2011
- Full Text
- View/download PDF
31. Myb proteins: angels and demons in normal and transformed cells.
- Author
-
Zhou Y and Ness SA
- Subjects
- Alternative Splicing physiology, Animals, Cell Cycle Proteins metabolism, Cell Differentiation drug effects, Cell Proliferation drug effects, Cell Transformation, Viral physiology, DNA-Binding Proteins metabolism, Humans, Leukemia genetics, MicroRNAs physiology, Neoplasms genetics, Neoplasms physiopathology, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-myb genetics, Signal Transduction, Stem Cells drug effects, Trans-Activators metabolism, Wnt Proteins physiology, Oncogene Proteins v-myb physiology, Proto-Oncogene Proteins c-myb physiology
- Abstract
A key regulator of proliferation, differentiation and cell fate, the c-Myb transcription factor regulates the expression of hundreds of genes and is in turn regulated by numerous pathways and protein interactions. However, the most unique feature of c-Myb is that it can be converted into an oncogenic transforming protein through a few mutations that completely change its activity and specificity. The c-Myb protein is a myriad of interactions and activities rolled up in a protein that controls proliferation and differentiation in many different cell types. Here we discuss the background and recent progress that have led to a better understanding of this complex protein, and outline the questions that have yet to be answered.
- Published
- 2011
- Full Text
- View/download PDF
32. Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study.
- Author
-
Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, Moir S, McCully RB, Pellikka PA, and Mulvagh SL
- Subjects
- Aged, Albumins adverse effects, Arrhythmias, Cardiac complications, Arrhythmias, Cardiac physiopathology, Blood Pressure, Cohort Studies, Echocardiography, Doppler, Color methods, Feasibility Studies, Female, Fluorocarbons adverse effects, Humans, Hypertension, Pulmonary complications, Hypertension, Pulmonary physiopathology, Image Enhancement methods, Male, Microbubbles, Middle Aged, Myocardial Infarction complications, Myocardial Infarction mortality, Retrospective Studies, Survival Analysis, Tricuspid Valve diagnostic imaging, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency physiopathology, Ventricular Dysfunction, Right complications, Ventricular Dysfunction, Right physiopathology, Contrast Media adverse effects, Echocardiography, Stress methods, Hypertension, Pulmonary diagnostic imaging, Myocardial Infarction etiology, Ventricular Dysfunction, Right diagnostic imaging
- Abstract
Background: Microbubble safety concerns led to changes in product recommendations for patients with pulmonary hypertension. Noninvasive estimation of right ventricular systolic pressure (RVSP) is equivalent to pulmonary artery systolic pressure in the absence of pulmonary outflow obstruction. We analyzed the short- and long-term outcomes of patients who received microbubble contrast and those who did not during stress echocardiography (SE) according to resting RVSP., Methods and Results: From November 2003 to December 2007, 26,774 patients underwent SE. RVSP (mean, 32.6+/-9.6 mm Hg) was measured in 16 434 patients. Of these, 6164 (37.5%) received contrast for left ventricular opacification and 10 270 (62.5%) did not. Short-term (< or =72 hours and < or =30 days) and long-term (4.3 years) end points were death and myocardial infarction. Analysis was done for rest RVSP cut-points > or =35, > or =50, and > or =60 mm Hg and tricuspid regurgitant velocities > or =2.7 ms(-1) and > or =3.5 ms(-1). Adjusted Cox regression models were used. The contrast cohort comprised older patients (age, 67+/-12 versus 64+/-14 years; P<0.001), who were more likely to have positive SE results (35% versus 30%, P<0.001) compared with the noncontrast cohort. Using RVSP > or =50 mm Hg, there was no significant difference in short-term events between the contrast and noncontrast cohorts. For long-term events, there was no significant difference between both cohorts (adjusted hazard ratios [95% confidence intervals] for death, 1.10 [0.80 to 1.50], P=0.56; and myocardial infarction, 0.34 [0.11 to 1.03], P=0.06). Similar results were obtained at different RVSP and tricuspid regurgitant cut-points. Contrast agent-related adverse effects occurred in <1% of patients., Conclusions: RVSP had no impact on predisposition to adverse outcomes in patients undergoing contrast SE in the population studied.
- Published
- 2010
- Full Text
- View/download PDF
33. Assessment of myocardial perfusion during adenosine stress using real time three-dimensional and two-dimensional myocardial contrast echocardiography: comparison with single-photon emission computed tomography.
- Author
-
Abdelmoneim SS, Bernier M, Dhoble A, Moir S, Hagen ME, Ness SA, Abdel-Kader SS, Pellikka PA, and Mulvagh SL
- Subjects
- Adenosine administration & dosage, Aged, Computer Systems, Contrast Media, Female, Fluorocarbons, Humans, Image Enhancement methods, Image Processing, Computer-Assisted methods, Male, Myocardial Perfusion Imaging, Observer Variation, Reproducibility of Results, Coronary Artery Disease diagnostic imaging, Echocardiography, Stress methods, Echocardiography, Three-Dimensional methods, Exercise Test methods, Tomography, Emission-Computed, Single-Photon methods
- Abstract
Objectives: To evaluate diagnostic accuracy of adenosine two-dimensional and three-dimensional myocardial contrast echocardiography (2D- and 3D-MCE) compared with single-photon emission computed tomography (SPECT) for assessing myocardial perfusion., Methods: From January through August 2007, patients with known or suspected CAD who were referred for SPECT underwent simultaneous adenosine 2D-MCE and 3D-MCE (live and full volume [FV]). Perfusion and wall motion in 17 segments in the left anterior descending, left circumflex, and right coronary artery territories were analyzed., Results: We studied 30 patients: mean (SD) age, 72.6 (8.2) years; 19 (63%) men. Perfusion by SPECT was abnormal in 13 patients (43%). When comparing MCE with SPECT, sensitivity was comparable for 2D-MCE, 92%; live 3D-MCE, 91%; and FV 3D-MCE, 90%. Specificity was comparable for 2D-MCE, 75%; live 3D-MCE, 69%; and FV 3D-MCE, 79%. Agreement between live 3D-MCE and 2D-MCE was 92% (kappa[SE], 0.83 [0.17]) and between FV 3D-MCE and 2D-MCE, 88% (kappa[SE], 0.76 [0.13]). For eight patients in whom SPECT showed reversible defects, live 3D-MCE correctly identified defects in seven (88%), whereas FV 3D-MCE correctly identified them in five (63%) (P = 0.57)., Conclusion: Myocardial perfusion assessment is feasible by 3D-MCE with the advantage of rapid, facile acquisition and offline image manipulation.
- Published
- 2010
- Full Text
- View/download PDF
34. Diagnostic accuracy of contrast echocardiography during adenosine stress for detection of abnormal myocardial perfusion: a prospective comparison with technetium-99 m sestamibi single-photon emission computed tomography.
- Author
-
Abdelmoneim SS, Bernier M, Dhoble A, Moir S, Hagen ME, Ness SA, Pellikka PA, Abdel-Kader SS, and Mulvagh SL
- Subjects
- Aged, Chi-Square Distribution, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease physiopathology, Feasibility Studies, Female, Humans, Likelihood Functions, Male, Microbubbles, Middle Aged, Observer Variation, Odds Ratio, Predictive Value of Tests, Prospective Studies, Reproducibility of Results, Sensitivity and Specificity, Adenosine, Contrast Media, Coronary Artery Disease diagnosis, Coronary Circulation, Echocardiography, Stress, Myocardial Perfusion Imaging methods, Radiopharmaceuticals, Technetium Tc 99m Sestamibi, Tomography, Emission-Computed, Single-Photon
- Abstract
Myocardial contrast echocardiography (MCE) utilizes compressible microbubbles behaving similarly to red blood cells. Destruction of microbubbles and observation of the gradual refill into the myocardium are key to evaluating perfusion using real-time MCE. We aimed to assess the feasibility and diagnostic accuracy of qualitative MCE utilizing a 17-segment model for localization of myocardial perfusion abnormalities compared with simultaneous technetium-99 m sestamibi single-photon emission computed tomography (SPECT). From July 2005 through August 2007, 97 patients with known or suspected coronary artery disease underwent simultaneous SPECT and realtime MCE during adenosine stress. Qualitative MCE and tracer uptake were analyzed visually using a 17-segment model in a blinded manner. Diagnostic accuracy and 95% confidence interval (CI) were determined. Myocardial contrast echocardiography was completed in 91 patients (age, mean [SD], 69.3 [10.9] years; body mass index, 30.0 [6.3]; 59 males [65%]). Myocardial contrast echocardiography analysis was feasible in 88 (97%) patients (261 of 264 [99%] territories; 1299 of 1497 [87%] segments). At patient level, MCE sensitivity was 88% (95% CI, 79%-94%); specificity was 85% (77%-90%). For disease detection in individual coronary territories, sensitivity and specificity were 84% (71%-92%) and 79% (72%-84%) for the left anterior descending artery; 62% (38%-80%) and 88% (83%-91%) for the left circumflex artery; and 73% (57%-82%) and 94% (89%-97%) for the right coronary artery. For MCE combined with wall-motion analysis, concordance with SPECT improved from 80% to 86%. Myocardial contrast echocardiography interobserver concordance was 81% (kappa [SE], 0.611 [0.78]). Myocardial contrast echocardiography accuracy was comparable in patients classified in accordance with presence of diabetes mellitus, myocardial infarction, hypertension, or percutaneous coronary intervention. Improved MCE specificity in detecting perfusion defects was seen in patients with no history of coronary bypass graft surgery (P = 0.005). Real-time MCE with a 17-segment model for analysis has good feasibility and accuracy in evaluation of myocardial perfusion during adenosine stress.
- Published
- 2010
- Full Text
- View/download PDF
35. Microvascular function in Takotsubo cardiomyopathy with contrast echocardiography: prospective evaluation and review of literature.
- Author
-
Abdelmoneim SS, Mankad SV, Bernier M, Dhoble A, Hagen ME, Ness SA, Chandrasekaran K, Pellikka PA, Oh JK, and Mulvagh SL
- Subjects
- Aged, Aged, 80 and over, Blood Flow Velocity, Chi-Square Distribution, Coronary Angiography, Female, Humans, Male, Microcirculation physiology, Prospective Studies, Takotsubo Cardiomyopathy physiopathology, Contrast Media administration & dosage, Echocardiography methods, Fluorocarbons administration & dosage, Takotsubo Cardiomyopathy diagnostic imaging
- Abstract
Background: Takotsubo cardiomyopathy (TC) mimics ST-elevation myocardial infarction without substantial angiographic stenosis. Coronary microvascular dysfunction has been proposed as a possible mechanism in TC. The aim of this study was to evaluate microvascular function in TC using real-time myocardial contrast echocardiography (MCE)., Methods: Real-time MCE was performed within 24 hours of coronary angiographic diagnosis of TC. Myocardial perfusion was evaluated through qualitative and quantitative myocardial contrast echocardiographic analyses comparing normal segments with segments with dysfunctional wall motion (WM)., Results: From January 2007 to January 2008, 11 patients received diagnoses of TC. Of these patients, 9 were prospectively enrolled (mean age, 70.9 +/- 17.5 years; 8 women). Qualitative and quantitative myocardial contrast echocardiographic analyses were feasible in 87% and 81% of segments. Overall, concordance between qualitative MCE and WM for normal versus abnormal analysis was observed in 71% of segments (kappa = 0.442, SE = 0.08). Significantly lower myocardial blood flow velocity (beta) and lower myocardial blood flow (Abeta) were detected in segments with dysfunctional WM compared with those with normal WM (beta = 0.55 +/- 0.39 vs 0.90 +/- 0.77, P = .009; Abeta = 5.31 +/- 3.92 vs 12.38 +/- 13.47, P = .002). In the discordant segments between qualitative MCE and WM, the quantitative perfusion parameters beta and Abeta were significantly lower in segments with dysfunctional WM compared with those with normal WM (beta = 0.22 +/- 0.20 vs 1.79 +/- 0.57, P = .01; Abeta = 1.90 +/- 1.1 vs 24.29 +/- 19.9, P = .02). Recovery of WM abnormalities was detected in all patients during follow-up echocardiography (mean, 60.3 +/- 66.0 days). No contrast-related side effects were reported. During mean follow-up of 5.9 +/- 4.6 months, there were no cardiac events, but 1 noncardiac death (from lung cancer) occurred., Conclusion: TC is associated with abnormal myocardial perfusion detected with qualitative and quantitative MCE, indicative of microvascular dysfunction.
- Published
- 2009
- Full Text
- View/download PDF
36. Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients.
- Author
-
Abdelmoneim SS, Bernier M, Scott CG, Dhoble A, Ness SA, Hagen ME, Moir S, McCully RB, Pellikka PA, and Mulvagh SL
- Subjects
- Aged, Arrhythmias, Cardiac mortality, Echocardiography, Stress mortality, Female, Humans, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Myocardial Infarction mortality, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Albumins adverse effects, Arrhythmias, Cardiac chemically induced, Contrast Media adverse effects, Echocardiography, Stress adverse effects, Exercise Test, Fluorocarbons adverse effects, Myocardial Infarction chemically induced
- Abstract
Objectives: We evaluated the short- and long-term safety of contrast agents during stress echocardiography (SE)., Background: Concerns about contrast agent safety led to revised recommendations for product use in the U.S., Methods: We studied 26,774 patients who underwent SE between November 1, 2003, and December 31, 2007. The 10,792 patients who comprised the contrast cohort received second-generation perfluorocarbon-based agents for left ventricular opacification during SE. The noncontrast cohort comprised 15,982 patients who had their first SE in the same period but without contrast agents. Short-term (< or = 72 h and < or = 30 days) and long-term (up to 4.5 years) end points were death and myocardial infarction (MI). Cox regression models were used. Immediate contrast agent-related adverse effects were also reported., Results: The contrast cohort had older patients (mean [SD] age, 65.8 [12.1] years vs. 62.6 [14.1] years; p < 0.001), a higher percentage of males (57.4% vs. 52.8%, p < 0.001), and higher-risk patients compared with the noncontrast cohort. In addition, dobutamine SE patients had greater cardiac risk than exercise SE patients. Abnormal SE findings in patients who received contrast agents were more frequent (32.4% vs. 27.9%, p < 0.001). The 2 cohorts had no statistical difference in the incidence of short-term events (death and MI). Within 72 h, 1 patient in the contrast cohort and 2 patients in the noncontrast cohort died (p = 0.54); 3 in the contrast cohort and 7 in the noncontrast cohort had MI (p = 0.92). Within 30 days, 37 patients (0.34%) in the contrast cohort and 57 patients (0.36%) in the noncontrast cohort died (p = 0.85); 17 patients (0.16%) in the contrast cohort and 16 patients (0.10%) in the noncontrast cohort had MI (p = 0.19). Adjusted hazard ratios were not different between cohorts for death (0.99; 95% confidence interval: 0.88 to 1.11) or MI (0.99; 95% confidence interval: 0.80 to 1.22)., Conclusions: The use of contrast agents during SE was not associated with an increased short-term or long-term risk of death or MI.
- Published
- 2009
- Full Text
- View/download PDF
37. Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation.
- Author
-
Fatema K, Gertz MA, Barnes ME, Eisinger AD, Ness SA, Gersh BJ, Micallef IN, Seward JB, Cha SS, Bailey KR, and Tsang TS
- Subjects
- Adult, Aged, Atrial Fibrillation etiology, Female, Humans, Incidence, Male, Middle Aged, Multiple Myeloma epidemiology, Retrospective Studies, Risk Factors, Time Factors, Atrial Fibrillation epidemiology, Body Weight, Diastole, Multiple Myeloma therapy, Stem Cell Transplantation
- Abstract
The management of atrial fibrillation (AF) following stem cell transplant (SCTX) is often challenging because of the universal presence of profound bone marrow suppression. The incidence of and risk factors for AF/flutter following SCTX are not well known. A total of 395 multiple myeloma (MM) patients consecutively underwent SCTX between 2002 and 2005 at the Mayo Clinic, and 383 of whom, mean age 57 +/- 9 years, had no history of evidence of AF/flutter constituted the study population. During 1,002 person-years of follow up, 39 (10%) patients developed first AF/flutter (incidence of 39 per 1,000 person years), and 28 of these (72%) occurred within 21 days of SCTX. In multivariable-adjusted analyses, weight gain of > or = 7% in the 1st week post-SCTX (HR 3.68; P = 0.0120) and presence of diastolic dysfunction at MM diagnosis (HR 2.294; P = 0.0082) were independent predictors of AF/flutter. The risk of AF/flutter post-SCTX increased by about ninefold when both factors were present. Compared to age and sex-matched MM patients without SCTX, the risk of AF/flutter differed significantly only over the 1st year after MM diagnosis, during which SCTX was performed for the majority. Beyond the 1st year, there was no significant difference in risk of AF/flutter between the two groups. The data suggested that SCTX was associated with significantly increased risk of first AF/flutter, which typically occurred within the first 21 days of the transplant. Weight gain of > or = 7% was strongly predictive of first AF/flutter, and the risk was augmented by the presence of diastolic dysfunction at baseline.
- Published
- 2009
- Full Text
- View/download PDF
38. The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.
- Author
-
Scariano JK, Treat E, Alba F, Nelson H, Ness SA, and Smith AY
- Subjects
- Age of Onset, Aged, Aged, 80 and over, Case-Control Studies, Disease Progression, Gene Expression Regulation, Neoplastic, Genetic Predisposition to Disease genetics, Genotype, Humans, Male, Middle Aged, Pilot Projects, Risk Factors, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase genetics, Adenocarcinoma genetics, Polymorphism, Single Nucleotide genetics, Prostatic Neoplasms genetics, Severity of Illness Index
- Abstract
Background: Emerging evidence indicates that testosterone (T), and not dihydrotestosterone (DHT), is the most relevant androgen that promotes carcinogenesis in the prostate. Steroid 5-alpha reductase type II (SRD5A2) catalyzes the irreversible conversion of T to DHT in male reproductive organs. Because the SRD5A2 gene is highly polymorphic at codon 89, two SRD5A2 isoforms are expressed that differ in K(m) and V(max) values. The more common and rapid catalytic isoform contains a valine residue at position 89; the slower-catalytic variant contains leucine at this position., Methods: Thirty-three men with early onset prostate cancer (PCa) were genotyped for the SRD5A2 V89L substitution and other polymorphisms in genes encoding receptors or enzymes that play important roles in pathways of steroid metabolism to ascertain if they were associated with standard clinical measures of disease progression at the time of diagnosis., Results: The expression of at least one SRD5A2 leucine allele in young men with PCa was associated with more significant disease at the time of presentation, as was defined by pretreatment PSA level, clinical staging and Gleason score when compared with affected subjects harboring the more common SRD5A2 valine variant. A dosage effect of a single leucine allele was evident in heterozygotes, as values of their clinical and pathological variables were consistently situated between the extremes of the homozygous V or L phenotypes., Conclusion: The SRD5A2 leucine isoform appears to be acting in a dose-dependent manner as a significant disease-modifying factor in young men diagnosed with PCa.
- Published
- 2008
- Full Text
- View/download PDF
39. Alternative RNA splicing produces multiple forms of c-Myb with unique transcriptional activities.
- Author
-
O'Rourke JP and Ness SA
- Subjects
- Acute Disease, Adenocarcinoma pathology, Adult, Binding Sites genetics, Breast Neoplasms pathology, Cell Line, Tumor metabolism, Child, Exons genetics, Female, Hematopoietic Stem Cells cytology, Hematopoietic Stem Cells metabolism, Humans, Jurkat Cells metabolism, K562 Cells metabolism, Leukemia genetics, Leukemia metabolism, Neoplasm Proteins genetics, Protein Isoforms genetics, Protein Isoforms physiology, Protein Structure, Tertiary, Proto-Oncogene Proteins c-myb physiology, Recombinant Fusion Proteins physiology, Structure-Activity Relationship, Alternative Splicing, Genes, myb, Proto-Oncogene Proteins c-myb genetics, Transcription, Genetic genetics
- Abstract
The c-Myb transcription factor regulates the proliferation and differentiation of hematopoietic cells, and activated alleles of c-myb induce leukemias and lymphomas in animals. Relatively minor changes in the structure of c-Myb protein change the genes that it regulates and can unleash its latent transforming activities. Here, quantitative assays were used to analyze the alternative splicing of human c-myb transcripts. We identified an array of variant transcripts, expressed in highly regulated, lineage-specific patterns, that were formed through the use of alternate exons 8A, 9A, 9B, 10A, 13A, and 14A. Expression levels of the different splice variant transcripts were regulated independently of one another during human hematopoietic cell differentiation, and the alternative splicing of c-myb mRNAs was increased in primary leukemia samples. The alternatively spliced c-myb transcripts were associated with polysomes and encoded a series of c-Myb proteins with identical DNA binding domains but unique C-terminal domains. In several types of assays, the variant c-Myb proteins exhibited quantitative and qualitative differences in transcriptional activities and specificities. The results suggest that the human c-myb gene encodes a family of related proteins with different transcriptional activities. Enhanced alternative splicing may be a mechanism for unmasking the transforming activity of c-myb in human leukemias.
- Published
- 2008
- Full Text
- View/download PDF
40. Microarray analysis: basic strategies for successful experiments.
- Author
-
Ness SA
- Subjects
- Animals, Humans, Mice, Rats, Research Design, Gene Expression Profiling methods, Oligonucleotide Array Sequence Analysis methods
- Abstract
Microarrays offer a powerful approach to the analysis of gene expression that can be used for a wide variety of experimental purposes. However, there are several types of microarray platforms that are available. In addition, microarray experiments are expensive and generate complicated data sets that can be difficult to interpret. Success with microarray approaches requires a sound experimental design and a coordinated and appropriate use of statistical tools. Here, the advantages and pitfalls of utilizing microarrays are discussed, as are practical strategies to help novice users succeed with this method that can empower them with the ability to assay changes in gene expression at the whole genome level.
- Published
- 2007
- Full Text
- View/download PDF
41. Mip/LIN-9 regulates the expression of B-Myb and the induction of cyclin A, cyclin B, and CDK1.
- Author
-
Pilkinton M, Sandoval R, Song J, Ness SA, and Colamonici OR
- Subjects
- Animals, Base Sequence, Cell Line, Tumor, Humans, Mice, Molecular Sequence Data, NIH 3T3 Cells, Nuclear Proteins, Tumor Suppressor Proteins metabolism, CDC2 Protein Kinase metabolism, Cell Cycle Proteins biosynthesis, Cyclin A physiology, Cyclin B physiology, DNA-Binding Proteins biosynthesis, Gene Expression Regulation, Trans-Activators biosynthesis, Tumor Suppressor Proteins physiology
- Abstract
Members of the novel family of proteins that include Drosophila Mip130, Caenorhabditis elegans LIN-9, and mammalian LIN-9 intervene in different cellular functions such as regulation of transcription, differentiation, transformation, and cell cycle progression. Here we demonstrate that LIN-9, designated as Mip/LIN-9, interacts with B-Myb but not with c-Myb or A-Myb. Mip/LIN-9 regulates the expression of B-Myb in a post-transcriptional manner, and its depletion not only decreases the level of the B-Myb protein but also affects the expression of S phase and mitotic genes (i.e. cyclin A, CDK1, and cyclin B). The critical role of Mip/LIN-9 on the expression of S and G(2)/M genes is further supported by the finding that coexpression of Mip/LIN-9 and B-Myb results in the activation of cyclin A and cyclin B promoter-luciferase reporters, and both proteins are detected on the cyclin A and B promoters. Interestingly, although Mip/LIN-9 promoter occupancy peaks earlier than B-Myb, the highest levels of expression of cyclins A and B correlate with the maximum binding of B-Myb to these promoters. These data support the concept that Mip/LIN-9 is required for the expression of B-Myb, and both proteins collaborate in the control of the cell cycle progression via the regulation of S phase and mitotic cyclins.
- Published
- 2007
- Full Text
- View/download PDF
42. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells.
- Author
-
Chand HS, Ness SA, and Kisiel W
- Subjects
- Adenocarcinoma genetics, Adenocarcinoma pathology, Base Sequence, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular pathology, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell pathology, Cytoplasm, Exons, Humans, Introns, Leukemia, Promyelocytic, Acute genetics, Leukemia, Promyelocytic, Acute pathology, Liver Neoplasms genetics, Liver Neoplasms pathology, Molecular Sequence Data, Neoplasm Staging, Neoplasms diagnosis, Neoplasms pathology, Pancreatic Neoplasms genetics, Pancreatic Neoplasms pathology, RNA analysis, RNA, Messenger analysis, Reverse Transcriptase Polymerase Chain Reaction, Thromboplastin analysis, Thromboplastin genetics, Tumor Cells, Cultured, Up-Regulation, Alternative Splicing, Neoplasms genetics, Thromboplastin biosynthesis
- Abstract
Tissue factor (TF) is a transmembrane glycoprotein that serves as the prime initiator of blood coagulation and plays a critical role in thrombosis and hemostasis. In addition, a variety of tumor cells overexpress cell-surface TF, which appears to be important for tumor angiogenesis and metastasis. To elucidate the mechanism involved in the upregulation of TF in human tumor cells, a comprehensive analysis of TF mRNA from various normal and tumor cells was performed. The results of these studies indicate that, in addition to possessing a normal full-length TF transcript and minor levels of an alternatively spliced transcript known as alternatively-spliced tissue factor (asTF), human tumor cells express additional full-length TF transcripts that are also generated by alternative splicing. Reverse transcriptase-polymerase chain reaction (RT-PCR) and 5'-rapid amplification of cDNA ends- (5'-RACE) based analyses of cytoplasmic RNA from normal and tumor cells revealed that there is alternative splicing of the first intron between exon I and exon II resulting in 2 additional TF transcripts. One of the transcripts has an extended exon I with inclusion of most of the first TF intron (955 bp), while the second transcript is formed by the insertion of a 495 bp sequence, referred to as exon IA, derived from an internal sequence of the first intron. The full length TF transcript with alternatively spliced novel exon IA, referred to as alternative exon 1A-tissue factor (TF-A), represented approximately 1% of the total TF transcripts in normal cells, but constituted 7-10% of the total TF transcript in tumor cells. Quantitative real-time RT-PCR analysis indicated that cultured human tumor cells contain 10-25-fold more copy numbers of TF-A in comparison to normal, untransformed cells. We propose that high-level expression of the novel TF-A transcript, preferentially in tumor cells, may have utility in the diagnosis and staging of a variety of solid tumors.
- Published
- 2006
- Full Text
- View/download PDF
43. Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb.
- Author
-
Liu F, Lei W, O'Rourke JP, and Ness SA
- Subjects
- Animals, Base Sequence, Cell Line, Tumor, DNA Primers, Humans, Oligonucleotide Array Sequence Analysis, Mutation, Oncogenes, Proto-Oncogene Proteins c-myb physiology, Transcription, Genetic genetics
- Abstract
The v-Myb oncoprotein encoded by Avian Myeloblastosis Virus is highly oncogenic, induces leukemias in chickens and mice and transforms immature hematopoietic cells in vitro. The v-Myb protein is a mutated and truncated version of c-Myb, a DNA-binding transcription factor expressed in many cell types that is essential for normal hematopoiesis. Previous studies suggested that two types of differences, DNA binding domain mutations and the deletion of a C-terminal negative regulatory domain were important for increasing the transforming activity of v-Myb. Here, we combined structure-function studies of the v-Myb and c-Myb proteins with unbiased microarray-based transcription assays to compare the transcriptional specificities of the two proteins. In human cells, the v-Myb and c-Myb proteins displayed strikingly different activities and regulated overlapping, but largely distinct sets of target genes. Each type of mutation that distinguished v-Myb from c-Myb, including the N- and C-terminal deletions, DNA binding domain changes and mutations in the transcriptional activation domain, affected different sets of target genes and contributed to the different activities of c-Myb and v-Myb. The results suggest that v-Myb is not just a de-repressed version of c-Myb. Instead, it is a distinct transcriptional regulator with a unique set of activities.
- Published
- 2006
- Full Text
- View/download PDF
44. Basic microarray analysis: strategies for successful experiments.
- Author
-
Ness SA
- Subjects
- Computational Biology, Gene Expression Profiling, Genomics, Humans, Data Interpretation, Statistical, Microarray Analysis
- Abstract
Microarrays offer a powerful approach to the analysis of gene expression that can be used for a wide variety of experimental purposes. However, several types of microarray platforms are available. In addition, microarray experiments are expensive and generate complicated data sets that can be difficult to interpret. Success with microarray approaches requires a sound experimental design and a coordinated and appropriate use of statistical tools. Here, the advantages and pitfalls of utilizing microarrays are discussed, as are practical strategies to help novice users succeed with this method that can empower them with the ability to assay changes in gene expression at the whole-genome level.
- Published
- 2006
- Full Text
- View/download PDF
45. Positive and negative regulation of c-Myb by cyclin D1, cyclin-dependent kinases, and p27 Kip1.
- Author
-
Lei W, Liu F, and Ness SA
- Subjects
- Amino Acid Sequence, Animals, Cell Cycle, Cell Cycle Proteins genetics, Cell Line, Chickens, Cyclin D1 genetics, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Cyclin-Dependent Kinase Inhibitor p27, Cyclin-Dependent Kinases antagonists & inhibitors, Cyclin-Dependent Kinases genetics, Humans, Mice, Molecular Sequence Data, Protein Binding, Protein Kinase Inhibitors pharmacology, Protein Structure, Tertiary, Proto-Oncogene Proteins antagonists & inhibitors, Proto-Oncogene Proteins c-myb chemistry, Proto-Oncogene Proteins c-myb genetics, Quail, Sequence Alignment, Transcriptional Activation, Tumor Suppressor Proteins genetics, Cell Cycle Proteins metabolism, Cyclin D1 metabolism, Cyclin-Dependent Kinases metabolism, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-myb metabolism, Tumor Suppressor Proteins metabolism
- Abstract
The c-Myb transcription factor controls differentiation and proliferation in hematopoietic and other cell types and has latent transforming activity, but little is known about its regulation during the cell cycle. Here, c-Myb was identified as part of a protein complex from human T cells containing the cyclin-dependent kinase (CDK) CDK6. Assays using model reporter constructs as well as endogenous target genes showed that the activity of c-Myb was inhibited by cyclin D1 plus CDK4 or CDK6 but stimulated by expression of the CDK inhibitors p16 Ink4a, p21 Cip1, or p27 Kip1. Mapping experiments identified a highly conserved region in c-Myb which, when transferred to the related A-Myb transcription factor, also rendered it responsive to CDKs and p27. The results suggest that c-Myb activity is directly regulated by cyclin D1 and CDKs and imply that c-Myb activity is regulated during the cell cycle in hematopoietic cells.
- Published
- 2005
- Full Text
- View/download PDF
46. Positive and negative determinants of target gene specificity in myb transcription factors.
- Author
-
Lei W, Rushton JJ, Davis LM, Liu F, and Ness SA
- Subjects
- Animals, Chickens, Genes, Reporter, Humans, Mutation, Oligonucleotide Array Sequence Analysis, Protein Structure, Tertiary, Proto-Oncogene Proteins c-myb genetics, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Transcription Factors genetics, Gene Expression Profiling, Gene Expression Regulation, Proto-Oncogene Proteins c-myb metabolism, Transcription Factors metabolism
- Abstract
The A-Myb and c-Myb transcription factors share a highly conserved DNA-binding domain and activate the same promoters in reporter gene assays. However, the two proteins have distinct biological activities, and expressing them individually in human cells leads to the activation of distinct sets of endogenous genes, suggesting that each protein has a unique transcriptional specificity. Here, the structural and functional features of the Myb proteins were compared, using assays of endogenous gene expression to measure changes in specificity. When the Myb proteins were tested in different cell types, they activated unique and nearly nonoverlapping sets of genes in each cellular context. Deletion and domain swap experiments identified small, discreet positive and negative elements in A-Myb and c-Myb that were required for the regulation of specific genes, such as DHRS2, DSIPI, and mim-1. The results suggest that individual functional elements in the transcriptional activation domains are responsible for activating specific cellular genes in a context-specific manner. The results also have important implications for interpreting results from reporter gene assays, which fail to detect the differences in activity identified through endogenous gene assays, and fusion protein constructs that alter the transcriptional activation domains and the activities of the Myb proteins.
- Published
- 2004
- Full Text
- View/download PDF
47. A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells.
- Author
-
Roitbak T, Ward CJ, Harris PC, Bacallao R, Ness SA, and Wandinger-Ness A
- Subjects
- Adherens Junctions metabolism, Cadherins metabolism, Cytoskeletal Proteins metabolism, Gene Expression Profiling, Humans, Phosphorylation, TRPP Cation Channels, Trans-Activators metabolism, beta Catenin, Cell Membrane metabolism, Epithelial Cells metabolism, Kidney metabolism, Polycystic Kidney Diseases metabolism, Proteins metabolism
- Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is typified by the accumulation of fluid-filled cysts and abnormalities in renal epithelial cell function. The disease is principally caused by mutations in the gene encoding polycystin-1, a large basolateral plasma membrane protein expressed in kidney epithelial cells. Our studies reveal that, in normal kidney cells, polycystin-1 forms a complex with the adherens junction protein E-cadherin and its associated catenins, suggesting a role in cell adhesion or polarity. In primary cells from ADPKD patients, the polycystin-1/polycystin-2/E-cadherin/beta-catenin complex was disrupted and both polycystin-1 and E-cadherin were depleted from the plasma membrane as a result of the increased phosphorylation of polycystin-1. The loss of E-cadherin was compensated by the transcriptional upregulation of the normally mesenchymal N-cadherin. Increased cell surface N-cadherin in the disease cells in turn stabilized the continued plasma membrane localization of beta-catenin in the absence of E-cadherin. The results suggest that enhanced phosphorylation of polycystin-1 in ADPKD cells precipitates changes in its localization and its ability to form protein complexes that are critical for the stabilization of adherens junctions and the maintenance of a fully differentiated polarized renal epithelium.
- Published
- 2004
- Full Text
- View/download PDF
48. Myb protein specificity: evidence of a context-specific transcription factor code.
- Author
-
Ness SA
- Subjects
- Cell Line, DNA-Binding Proteins genetics, Down-Regulation, Fibroblasts cytology, Genetic Code, Humans, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-myb genetics, Signal Transduction, Trans-Activators genetics, Transcription Factors genetics, Transcription Factors metabolism, Transcriptional Activation, Cell Cycle Proteins, DNA-Binding Proteins metabolism, Gene Expression Regulation, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-myb metabolism, Trans-Activators metabolism
- Abstract
Vertebrates express three different Myb family transcription factors, A-Myb, B-Myb, and c-Myb, that share a highly conserved DNA binding domain, bind to the same DNA sequences, and activate the same reporter gene constructs in transfection assays. However, the three Myb proteins have completely different biological roles, and microarray assays have shown that ectopic expression of each protein causes the activation of different sets of human genes. Furthermore, the genes that are activated by each protein in different cell types are distinct, suggesting that Myb transcription factors are subject to context-specific regulatory mechanisms. The data support a modification code model in which Myb proteins become decorated with different sets of posttranslational modifications in different cell types, and these modifications control the ability of the Myb proteins to interact with other cellular components that are required for activating specific sets of genes.
- Published
- 2003
- Full Text
- View/download PDF
49. Pim-1 phosphorylates the DNA binding domain of c-Myb.
- Author
-
Winn LM, Lei W, and Ness SA
- Subjects
- Animals, Binding Sites genetics, Cells, Cultured, Chick Embryo, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Eukaryotic Cells cytology, Phosphorylation, Protein Serine-Threonine Kinases genetics, Protein Structure, Tertiary genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-myb genetics, Proto-Oncogene Proteins c-pim-1, Signal Transduction genetics, Cell Differentiation genetics, Cell Division genetics, Eukaryotic Cells metabolism, Protein Serine-Threonine Kinases metabolism, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-myb metabolism, Transcription, Genetic genetics
- Abstract
The c-Myb transcription factor regulates cellular differentiation and proliferation and is regulated by complex mechanisms that control its repressed oncogenic activity. The transcriptional activity of c-Myb is regulated by the serine/threonine protein kinase Pim-1. Here, we show that Pim-1 is able to interact with c-Myb and the closely related transcription factor A-Myb, via direct interactions with the highly conserved Myb DNA binding domain. Pim-1 associated with Myb both in cells and in vitro, and phosphorylated the Myb DNA binding domain, suggesting that it regulates Myb protein activity by direct phosphorylation.
- Published
- 2003
50. Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins.
- Author
-
Rushton JJ, Davis LM, Lei W, Mo X, Leutz A, and Ness SA
- Subjects
- Adenoviridae genetics, Breast cytology, Breast physiology, Cell Line, Transformed, Cells, Cultured, Epithelial Cells, Female, Gene Expression Regulation, Humans, Keratins genetics, Oligonucleotide Array Sequence Analysis, Cell Cycle Proteins, DNA-Binding Proteins genetics, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins c-myb genetics, Trans-Activators genetics
- Abstract
The c-Myb, A-Myb and B-Myb transcription factors have nearly identical DNA-binding domains, activate the same reporter gene constructs in animal cells, but have different biological roles. The Myb proteins are often coexpressed in the same cells, raising questions about whether they activate similar or distinct gene expression profiles, and whether they cooperate or compete in regulating the same promoters. Here, recombinant adenoviruses were used to express each protein in human mammary cells, and then microarray assays were used to assess global changes in gene expression. Each Myb protein induced a unique and specific set of changes, displaying activities far more complex than revealed by standard reporter gene assays. These results have important implications for the roles of various Myb proteins in normal and transformed human cells, for regulatory pathways that might modify their activities and for the importance of acquired mutations that may qualitatively alter their functions in tumors.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.